WO2007128537A3 - Pharmazeutische zubereitung auf der basis von myrtucommulon a zur selektiven tumor- und krebstherapie - Google Patents

Pharmazeutische zubereitung auf der basis von myrtucommulon a zur selektiven tumor- und krebstherapie Download PDF

Info

Publication number
WO2007128537A3
WO2007128537A3 PCT/EP2007/003989 EP2007003989W WO2007128537A3 WO 2007128537 A3 WO2007128537 A3 WO 2007128537A3 EP 2007003989 W EP2007003989 W EP 2007003989W WO 2007128537 A3 WO2007128537 A3 WO 2007128537A3
Authority
WO
WIPO (PCT)
Prior art keywords
myrtucommulone
lipophilic extract
pharmaceutical preparation
cancer therapy
preparation based
Prior art date
Application number
PCT/EP2007/003989
Other languages
English (en)
French (fr)
Other versions
WO2007128537A2 (de
Inventor
Oliver Werz
Irina Tretiakova
Original Assignee
Univ Eberhard Karls
Oliver Werz
Irina Tretiakova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Eberhard Karls, Oliver Werz, Irina Tretiakova filed Critical Univ Eberhard Karls
Priority to EP07724913A priority Critical patent/EP2026781A2/de
Publication of WO2007128537A2 publication Critical patent/WO2007128537A2/de
Publication of WO2007128537A3 publication Critical patent/WO2007128537A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Myrtucommulon A, als lipophiler Extrakt aus Myrte oder in synthetisch hergestellter Form, oder einer pharmazeutischen Zusammensetzung, die das so erhaltene Myrtucommulon A aufweist, zur Herstellung eines Arzneimittels zur Beeinflussung des Zellwachstums, insbesondere zur selektiven Hemmung einer atypischen Zellproliferation, z. B. bei Krebs. Bevorzugt wird der lipophile Extrakt aus Myrtenblättern gewonnen, besonders in gereinigter Form. Die Reinigung wird dadurch erreicht, daß der lipophile Extrakt von Myrtucommulon A in mehreren Schritten aufgearbeitet und eingeengt, nach zumindest einem Teil der Aufarbeitungsschritte jeweils mit einem Lösungsmittel wieder aufgenommen, gegebenenfalls gefiltert und erneut extrahiert und anschließend Myrtucommulon A im wesentlichen als Reinsubstanz durch chromatographische Auftrennung erhalten wird.
PCT/EP2007/003989 2006-05-06 2007-05-07 Pharmazeutische zubereitung auf der basis von myrtucommulon a zur selektiven tumor- und krebstherapie WO2007128537A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07724913A EP2026781A2 (de) 2006-05-06 2007-05-07 Pharmazeutische zubereitung auf der basis von myrtucommulon a zur selektiven tumor- und krebstherapie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006021154.5 2006-05-06
DE102006021154A DE102006021154A1 (de) 2006-05-06 2006-05-06 Zubereitungen aus Myrte, ihren Inhaltsstoffen und/oder deren Derivaten zur Therapie von Krebserkrankungen

Publications (2)

Publication Number Publication Date
WO2007128537A2 WO2007128537A2 (de) 2007-11-15
WO2007128537A3 true WO2007128537A3 (de) 2008-06-12

Family

ID=38564918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/003989 WO2007128537A2 (de) 2006-05-06 2007-05-07 Pharmazeutische zubereitung auf der basis von myrtucommulon a zur selektiven tumor- und krebstherapie

Country Status (3)

Country Link
EP (1) EP2026781A2 (de)
DE (1) DE102006021154A1 (de)
WO (1) WO2007128537A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006058450A1 (de) * 2006-12-12 2008-06-19 Eberhard-Karls-Universität Tübingen Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
CN108864011B (zh) * 2017-05-15 2021-06-29 南方科技大学 抗菌药物的制备方法
CN112516134B (zh) * 2019-09-18 2023-06-06 上海医药集团股份有限公司 一种含羟基的化合物在制备药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016791A1 (fr) * 1998-09-17 2000-03-30 Pierre Fabre Dermo-Cosmetique Extrait de myrte, procede de preparation et application
WO2000050053A1 (en) * 1995-02-15 2000-08-31 Kass Chaim David Natural product composition for use in treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050053A1 (en) * 1995-02-15 2000-08-31 Kass Chaim David Natural product composition for use in treating cancer
WO2000016791A1 (fr) * 1998-09-17 2000-03-30 Pierre Fabre Dermo-Cosmetique Extrait de myrte, procede de preparation et application

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALI H ALWAN ET AL: "EFFECTS OF PLANT EXTRACTS ON ARYL HYDROCARBON HYDROXYLASE ACTIVITY AND 3H-BENZO(A9PYRENE BINDING TO DNA", JOURNAL OF FOOD SAFETY, XX, XX, vol. 10, no. 3, 1990, pages 209 - 218, XP002114716, ISSN: 0149-6085 *
TRETIAKOVA IRINA ET AL: "Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9.", APOPTOSIS : AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH JAN 2008, vol. 13, no. 1, January 2008 (2008-01-01), pages 119 - 131, XP002473960, ISSN: 1360-8185 *

Also Published As

Publication number Publication date
EP2026781A2 (de) 2009-02-25
WO2007128537A2 (de) 2007-11-15
DE102006021154A1 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2007096119A3 (en) Method for purification of 225ac from irradiated 226ra-targets
WO2012082718A3 (en) 3-methanesulfonylpropionitrile for treating inflammation and pain
CN102228514B (zh) 一种从油橄榄叶中提取橄榄苦苷的方法
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2007066017A3 (fr) Procede de preparation d'un concentre de facteur h et utilisation de ce concentre de facteur h au titre de medicament
WO2010067286A3 (en) IgE CH3 PEPTIDE VACCINE
JP2010525051A5 (de)
WO2006081445A3 (en) Treatment of metastasized tumors
CN101838299B (zh) 一种天然麦角甾苷的分离纯化方法
WO2007128537A3 (de) Pharmazeutische zubereitung auf der basis von myrtucommulon a zur selektiven tumor- und krebstherapie
CN103304611B (zh) 一种从瓜蒌皮中分离纯化3种黄酮苷的方法
CN106045960B (zh) 一种从高良姜中提取二苯基庚烷类物质的方法
KR101123102B1 (ko) 초고압 재결정화 방법을 이용하여 녹차로부터 ｅｇｃｇ를 분리, 정제하는 방법
CN104341379A (zh) 一种高良姜素的提取方法
CN104327066A (zh) 快速高效提取卡柏林类生物碱的方法
WO2013019977A3 (en) Extraction, purification, and processing of phytoglycogen
UA87114C2 (ru) Способ получения экстракта из листьев плюща, экстракт, его применение и лекарственное средство
WO2007113266A3 (en) Novel compounds and methods for their production
CN104447780B (zh) 一种从芝麻中提取芝麻素的方法
MX343308B (es) Procedimiento para preparar un extracto enriquecido a partir de hojas de vitis vinifera l.
KR20120024176A (ko) 초고압 재결정화 방법을 이용하여 약용식물로부터 활성물질을 분리, 정제하는 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07724913

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007724913

Country of ref document: EP